Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2025
4,437
Period ended Dec 28, 2025
Change on a year earlier
+3.6%
4,282 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 4,437 | +3.6% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 4,282 | +12.2% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 3,815 | +11.6% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 3,417 | -1.0% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Jan 2, 2022 | 3,450 | +9.6% | Form 10-K (filed 2024-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 3,148 | +20.0% | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 2,623 | +1.9% | Form 10-K (filed 2022-02-17) ↗ |
| FY2018 | Dec 30, 2018 | 2,573 | +93.9% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 1,327 | – | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 0 | – | Form 10-K (filed 2019-02-20) ↗ |
Breakdown
What makes up pulmonary hypertension (ph) therapeutic area total — worldwide sales ($m)
- Pulmonary Hypertension (PH) Therapeutic Area Total — U.S. sales ($M)3,223 · FY2025
- Pulmonary Hypertension (PH) Therapeutic Area Total — International sales ($M)1,214 · FY2025
- Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide reported growth YoY (%)3.6% · FY2025
- Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)3.2% · FY2025
- UPTRAVI (selexipag) — Worldwide sales ($M)1,902 · FY2025
- OPSUMIT / OPSYNVI (macitentan) — Worldwide sales ($M)2,325 · FY2025
- TRACLEER (bosentan) [reported separately through FY2019Q4] — Worldwide sales ($M)341 · FY2019
- Other Pulmonary Hypertension medicines — Worldwide sales ($M)209 · FY2025
Cite this data
StockData. (2026). Johnson & Johnson Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ta_pulm_hypertension
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.